Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-3: KTE-X19 in relapsed/refractory B-precursor acute lymphoblastic leukemia
NL-OMON54807Phase 2Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- May 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Kite Pharma. Primary endpoints: Incidence of dose-limiting toxicities and Overall complete remission rate. Started May 2019; status: active, not recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON54807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54807.